Carcinogenesis

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (143) Request Permissions Google Scholar Articles by Wargovich, M. J. Articles by Kelloff, G. J. Search for Related Content PubMed PubMed Citation Articles by Wargovich, M. J. Articles by Kelloff, G. J. Social Bookmarking          What's this?

Carcinogenesis, Vol. 21, No. 6, 1149-1155, June 2000
© 2000 Oxford University Press

Molecular Epidemiology and Cancer Prevention

Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression

Michael J. Wargovich⁴, Arnaldo Jimenez¹, Kathy McKee¹, Vernon E. Steele³, Marco Velasco¹, Johnnie Woods¹, Roger Price², Kenneth Gray² and Gary J. Kelloff³

Division of Basic Research, South Carolina Cancer Center, Columbia, SC 29203,
¹ Department of Gastrointestinal Medical Oncology and Digestive Diseases and
² Division of Veterinary Medicine and Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 and
³ Chemoprevention Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA

	Abstract

Top Abstract Introduction Materials and methods Results Discussion References

 
We assessed the effects of 78 potential chemopreventive agents in the F344 rat using two assays in which the inhibition of carcinogen-induced aberrant crypt foci (ACF) in the colon was the measure of efficacy. In both assays ACF were induced by the carcinogen azoxymethane (AOM) in F344 rats by two sequential weekly injections at a dose of 15 mg/kg. Two weeks after the last AOM injection, animals were evaluated for the number of aberrant crypts detected in methylene blue stained whole mounts of rat colon. In the initiation phase protocol agents were given during the period of AOM administration, whereas in the post-initiation assay the chemopreventive agent was introduced during the last 4 weeks of an 8 week assay, a time when ACF had progressed to multiple crypt clusters. The agents were derived from a priority listing based on reports of chemopreventive activity in the literature and/or efficacy data from in vitro models of carcinogenesis. During the initiation phase carboxyl amidoimidazole, p-chlorphenylacetate, chlorpheniramine maleate, D609, diclofenac, etoperidone, eicosatetraynoic acid, farnesol, ferulic acid, lycopene, meclizine, methionine, phenylhexylisothiocyanate, phenylbutyrate, piroxicam, 9-cis-retinoic acid, S-allylcysteine, taurine, tetracycline and verapamil were strong inhibitors of ACF. During the post-initiation phase aspirin, calcium glucarate, ketoprofen, piroxicam, 9-cis-retinoic acid, retinol and rutin inhibited the outgrowth of ACF into multiple crypt clusters. Based on these data, certain phytochemicals, antihistamines, non-steroidal anti-inflammatory drugs and retinoids show unique preclinical promise for chemoprevention of colon cancer, with the latter two drug classes particularly effective in the post-initiation phase of carcinogenesis.

Abbreviations: ACF, aberrant crypt foci; AOM, azoxymethane; CAI, carboxyl amidoimidazole; ETYA, eicosatetraynoic acid; NSAID, non-steroidal anti-inflammatory drug; PHITC, phenylhexylisothiocyanate.

	Introduction

Top Abstract Introduction Materials and methods Results Discussion References

 
We have previously reported on the efficacy of a number of natural and synthetic compounds as potential chemopreventives for colon cancer using the induction of aberrant crypt foci (ACF) as the primary end-point (1). ACF are preneoplastic lesions in rat colon (2–4). They are induced by all known colon carcinogens and exhibit a number of molecular mutations in regulatory genes consonant with the development of human colon cancer, most notably in the ras oncogene and apc tumor suppressor gene (5,6). In our initial study we only evaluated the potential chemopreventive agents during the initiation phase of carinogenesis. We recognized that compounds acting in the post-initiation period could result in false negatives in the assay. With this in mind we developed a post-initiation protocol for the evaluation of potential chemopreventive agents on established ACF in the rat colon and found that certain non-steroidal anti-inflammatory drugs (NSAIDs) were powerful suppressors of aberrant crypt growth and progression (7). This protocol clearly has more clinical relevance since it may identify candidate agents that prove useful in preventing the recurrence and progression of precursor lesions for colon cancer. In the current study we report on the further evaluation of 78 agents for the prevention of colon cancer. Specifically, we have evaluated the activity of 30 agents in the post-initiation protocol. The data suggest that two classes of drugs, the NSAIDs and retinoids, act strongly in the post-initiation phase of carcinogenesis of the colon.

	Materials and methods

Top Abstract Introduction Materials and methods Results Discussion References

 
Animals, diets, test agents and carcinogens
Male F344 rats were purchased at 6 weeks of age from Harlan Sprague-Dawley (Wilmington, MA), were quarantined for 5 days and then housed in standard cages and with standard bedding in the animal facility on a 12 h light–dark cycle, at 50% relative humidity, with continual access to drinking water. At 7 weeks of age, all rats were fed the AIN-76A diet (Dyets Inc., Bethlehem, PA) on which they remained for the duration of the experiment. For each agent to be tested, 40 rats were randomized into groups of 10. The groups were: (i) negative control (no test agent, no carcinogen); (ii) positive control (no test agent, with carcinogen); (iii) and (iv) treatment groups (test agent and carcinogen). The positive and negative controls were fed the standard AIN-76A diet throughout the experiment duration. The treatment groups had either 40 or 80% of the maximum tolerated dose of each agent included in their diets; these doses are known not to cause a decrement in body weight over a 5 week experimental period. Doses were chosen based on communication with the National Cancer Institute, published data or proprietary information. In the initiation protocol (protocol A) (Figure 1), the diets were fed to the rats beginning 1 week prior to injection with the carcinogen or saline, then continuously for the next 4 weeks. In the post-initiation protocol (protocol B) (Figure 1), the test agent was administered beginning at week 5 and administered continuously in the feed until the end of week 8, when the animals were killed. The test agents used in the study were procured at the highest available purity from a variety of sources: amiloride, aspirin, bromoergocryptine, calcium glucarate, p-carbenoxalone, chloropheniramine maleate, 13-cis-retinoic acid, cimetidine, farnesol, ferulic acid, folic acid, geranyl geraniol, glycine, ibuprofen, meclizine, meclofenamate, melatonin, l-methionine, p-methoxyphenol, nicotinic acid, piroxicam, polyvinylpyrrolidone, promethazine, quinacrine HCl, retinol, rutin, d,l-selenomethionine, stevioside, taurine, tetracycline, theophylline, tolmetin, all-trans-retinoic acid, triprolidine, ursolic acid and verapamil were purchased from Sigma Chemical Co. (St Louis, MO). 2-n-Butylthiophene was purchased from Lancaster Synthesis Ltd (Windham, NH). Esculetin, nerolidol and 1,2-oxothiazolidine 4-carboxylate were purchased from Aldrich Chemical Co. (Milwaukee, WI). Eicosatetraynoic acid (ETYA) was purchased from Biomol Inc. (Plymouth Meeting, PA). Diallyl disulfide was purchased from Pfaltz and Bauer Inc. (Waterbury, CT). Perillyl alcohol was purchased from CTC Organics (Atlanta, GA). Several companies provided their reagents as gifts for research: S-allylcysteine (Wakunaga Pharmaceutical Co., Hiroshima, Japan), difluoromethylornithine (Marion-Merrill Dow, Cincinnati, OH), ketoprofen (Rhone-Poulenc, Vitry-Sur-Seine, France), Ro16-9100 (Hoffman-LaRoche Inc., Nutley, NJ), sulindac and its metabolites (Cell Pathways, Aurora, CO) and tea extracts (Lipton, Englewood Cliffs, NJ). All other agents were provided by the National Cancer Institute Chemical Repository. For several agents random spot checks on the stability of the test agent in the diet were performed using HPLC, but not for all agents tested. All diets were made fresh weekly and held at –20°C prior to placement in the animal diet jars.

View larger version (45K): [in this window] [in a new window]   Fig. 1. Experimental schema. Shading indicates phase when test agent was present in the experimental diet.

 
For both protocols, the positive control group and the two treatment groups were injected i.p. with the carcinogen azoxymethane (AOM) purchased from Ash Stevens Inc. (Detroit, MI) twice weekly (weeks 2 and 3 of each experiment) at a dose level of 15 mg/kg body wt. The negative control group was injected with saline in place of AOM. At the end of week 5 (initiation protocol A) and at the end of week 8 (post-initiation protocol B) of each experiment the rats were killed by CO₂ asphyxiation and the colon removed for evaluation of aberrant crypts. This study was approved by the Insitutional Animal Care and Use Committee at The University of Texas M.D. Anderson Cancer Center (protocol 11-8807832).

Aberrant crypt assay
The colons were removed and flushed with cold phosphate-buffered saline, then cut open along the longitudinal median and fixed flat in 10% buffered formalin for 24 h. The method of Tudek et al. (4) was used to stain and highlight ACF. For each test agent the number of ACF was evaluated in the 0.3% methylene blue stained colon by two scorers unaware of the treatment assignment. We scored ACF under 40x magnification using a Nikon dissecting microscope with a fiber optic light source to transluminate the colon. The study consisted of multiple experiments. Experiments usually involved the testing of four compounds at a particular time over a period of 18 months. The number of ACF in the AOM-treated controls ranged from 73 to 240 over the course of the study, but efficacy was always assessed against the AOM controls within each experimental set.

Statistical analysis
All data were analyzed using Sigmastat software (SPSS, Chicago, IL). Both treatment doses were compared with the AOM-only group using one-way ANOVA. If a significant difference (P < 0.05) was observed we used the Bonferroni t-test as a multiple comparison test. The data were also tested for normality; if the data were not normally distributed we used the non-parametric Kruskal–Wallis test for multiple comparisons.

	Results

Top Abstract Introduction Materials and methods Results Discussion References

 
Table I lists the agents that we evaluated in the initiation protocol, which tested for chemopreventive effects during the time of exposure to AOM. The most inhibitory compounds were p-chlorophenylacetate, chlorpheniramine maleate, carboxyl amidoimidazole (CAI), D609, diclofenac, ETYA, etoperidone, farnesol, ferulic acid, lycopene, meclizine, l-methionine, phenylhexylisothiocyanate (PHITC), sodium phenylbutyrate, piroxicam, 9-cis-retinoic acid, S-allylcysteine, taurine, tolmetin, tetracycline, triprolidine, verapamil and WR151327. These data when combined with those from our previous study continue to suggest that NSAID compounds (e.g. diclofenac and piroxicam), certain plant phenolics or flavonoids (ferulic acid), isothiocyanates (PHITC) and organosulfur compounds (S-allylcysteine) may in some way modulate AOM metabolism or modify early cellular events in the process of aberrant crypt formation. One class of chemicals, the antihistamines, represented in this study by chlorpheniramine maleate, meclizine and triprolidine (but not promethazine), were very effective suppressors of ACF during initiation. Some compounds tested produced mixed dose–effect results, inhibiting at one but not both doses tested. This pattern was found for tea polyphenolics and the farnesylation inhibitors farnesol and geranyl geraniol, among others. Several compounds promoted the development of ACF (increased ACF number or multiplicity) either at one or both doses tested. These included 2-n-butylthiophene, carbenoxalone, green and black tea extracts, meclofenamate, p-methoxyphenol, nerolidol, 1,2-oxothiazolidine 4-carboxylate and quinacrine HCl.

View this table: [in this window] [in a new window]   Table I. Effect of test agents on AOM-induced ACF in rat colon during the initiation phase

 
Table II lists the agents that we evaluated in the post-initiation assay. We devised this protocol to address the need for a variation of the assay that would identify posssible chemopreventive compounds acting to regress or retard the outgrowth of ACF into microadenomas, precursors to colon cancer. The data suggest that there are two chemical classes of agents that were significantly effective in this respect, the NSAIDs and certain retinoids. From the NSAID class, aspirin, diclofenac, ketoprofen, piroxicam and sulindac and its metabolites sulindac sulfide and sulindac sulfone were strongly inhibitory toward ACF outgrowth and progression into larger lesions. From the retinoid class, 4-hydroxyphenretinamide, all-trans retinoic acid, 9-cis-retinoic acid, 13-cis-retinoic acid and retinol significantly inhibited ACF progression. This effect is also evident in an arrest of outgrowth of ACF into multiple crypt clusters (crypt multiplicity). This is shown for the sulindac compounds in Figure 2 and for representative members of the retinoid class in Figure 3.

View this table: [in this window] [in a new window]   Table II. Effect of test agents on AOM-induced aberrant crypt foci in rat colon during the post-initiation phase

 

View larger version (35K): [in this window] [in a new window]   Fig. 2. Effect of sulindac and sulindac metabolites on ACF progression. Compounds were given in the diet post-initiation following AOM. Values are means ± SD. *Significantly different from the control at P < 0.05.

 

View larger version (40K): [in this window] [in a new window]   Fig. 3. Effect of selected retinoids on ACF progression. Compounds were given in the diet post-initiation following AOM. Values are means ± SD. *Significantly different from the control at P < 0.05.

 

	Discussion

Top Abstract Introduction Materials and methods Results Discussion References

 
In this study we have used two variations of an experimental protocol designed to screen potential chemopreventive agents for efficacy in reducing the incidence of ACF, carcinogen-induced precursors of colon cancer. ACF are an appropriate target for chemopreventive drug development as increasing evidence suggests them to be in the pathway leading to colon cancer (8–11). Studies characterizing ACF at the molecular and cellular levels implicate ACF as intermediate lesions leading to colon cancer. ACF in rats and humans exhibit defects in DNA content, morphology and proliferation kinetics and mutations have been detected in key genes in the process of colon cancer development (10,12–18). Recent studies also hint that ACF are precursors of colon cancer in humans and this further stimulates the need to identify drugs that may prevent their progression (11,19–21).

In this report we have evaluated a number of compounds for the ability to prevent ACF in the well-studied AOM colon cancer model in the rat. The agents chosen for the study were prioritized by reports of previous activity in the research literature, by a beneficial finding in in vitro chemopreventive protocols conducted by the National Cancer Institute or by communication with the National Cancer Institute. The data suggest that during the initiation phase of AOM carcinogenesis two classes of agents are active inhibitors, the antihistamines (chlorpheniramine, meclizine and triprolidine) and a group of plant phytochemicals (ferulic acid, lycopene and S-allylcysteine). We also noted some chemopreventive activity for the differentiation agents p-chlorophenylacetate and phenylbutyrate. Chlorpheniramine, meclizine and triprolidine are members a family of drugs that function as histamine H₁ receptor antagonists and are widely used in the control of allergies (22,23). The results found in our study are not readily explained, although antiproliferative effects have been reported for chlorpheniramine on breast cancer cells in vitro and this antihistamine and triprolidine are known to modulate certain cytochromes P450 in rats (24–26). Ferulic acid has been shown to prevent oral and skin cancer in rodents, while lycopene has been implicated as a possible anticarcinogen in human diets and may protect against prostate cancer (26–29). Few chemopreventive experiments with lycopene have been done in animals. PHITC, a synthetic isothiocyanate, and S-allylcysteine from alliums probably exert their effects through modulation of carcinogen metabolism (30,31). PHITC modulates CYP2E1 but has been shown to promote the induction of esophageal carcinogenesis despite earlier reports of chemopreventive activity, whereas S-allylcysteine, an inhibitor of CYP2E1, prevents dimethylhydrazine-induced colon cancer in mice (32–34). The unsubstituted and substituted phenyl fatty acids p-chlorophenylacetate and phenylbutyrate both showed chemopreventive effects in the initiation phase assay. Both compounds are powerful differentiation agents and are used in cancer chemotherapy (35). Phenylbutyrate is known to be a potent inducer of apoptosis and agents that strongly induce apoptosis (the NSAIDS for example) are good chemopreventives in the rat colon cancer model (7,36–38).

This study also conducted an in-depth evaluation of agents selected for a high probability of acting as preventives in the post-initiation phase against established ACF. The protocol described may better identify agents for further preclinical evaluation that retard the growth or regress ACF in vivo. Such agents would be likely to prevent recurrence of colonic adenoma in humans. From the NSAID class, aspirin, diclofenac, ibuprofen (high dose), ketoprofen, piroxicam and sulindac and its metabolites strongly suppressed ACF incidence and crypt multiplicity. A decrement in crypt multiplicity suggests that the compound may be acting in a cytostatic or bio-regressive way. Many of the agents we tested in this study have been shown to prevent colon cancer in the long term. Additionally, for the NSAID class in particular, habitual consumption results in a reduced risk for colon cancer (39,40). The study also identified several retinoids as effective suppressors of established ACF, notably 4-hydroxyphenretinamide, all-trans-retinoic acid, 9-cis-retinoic acid, 13-cis-retinoic acid and retinol. Many of these compounds have already entered clinical trials for prevention of tumors other than in the colon (41–47). The results suggest that consideration should be given to the potential use of retinoids for suppression of preneoplasia in the colon. The rodent ACF assay is a powerful screening tool for the preclinical identification of chemopreventive agents with high sensitivity and specificity (48). The findings of this study provide an impetus for further in-depth evaluation of the NSAIDs and retionids and other compounds in the prevention of colon cancer.

	Notes

 
⁴ To whom correspondence should be addressed Email: michael.wargovich{at}rmh.edu

	Acknowledgments

 
The authors wish to thank Robert Preston for technical assistance. This work was supported in part by NCI Research Contracts NO1-CN-85151-03 and NO1-CN-35570-01 to M.J.W. and by Cancer Center Support Grant CA-16672 from the NIH.

	References

Top Abstract Introduction Materials and methods Results Discussion References

 

1. Wargovich,M.J., Chen,C.D., Jimenez,A., Steele,V.E., Velasco,M., Stephens,L.C., Price,R., Gray,K. and Kelloff,G.J. (1996) Aberrant crypts as a biomarker for colon cancer – evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol. Biomarkers Prev., 5, 355–360.[Abstract/Free Full Text]
2. McLellan,E.A. and Bird,R.P. (1988) Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res., 48, 6187–6192.[Abstract/Free Full Text]
3. Bird,R.P., McLellan,E.A. and Bruce,W.R. (1989) Aberrant crypts, putative precancerous lesions, in the study of the role of diet in the aetiology of colon cancer. Cancer Surv., 8, 189–200.[Web of Science][Medline]
4. Bilbin,M., Tudek,B. and Czeczot,H. (1992) Induction of aberrant crypts in the colons of rats by alkylating agents. Acta Biochim. Pol., 39, 113–117.[Web of Science][Medline]
5. Vivona,A.A., Shpitz,B., Medline,A., Bruce,W.R., Hay,K., Ward,M.A., Stern,H.S. and Gallinger,S. (1993) K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis, 14, 1777–1781.[Abstract/Free Full Text]
6. Smith,A.J., Stern,H.S., Penner,M., Hay,K., Mitri,A., Bapat,B.V. and Gallinger,S. (1994) Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res., 54, 5527–5530.[Abstract/Free Full Text]
7. Wargovich,M.J., Chen,C.D., Harris,C., Yang,E. and Velasco,M. (1995) Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int. J. Cancer, 60, 515–519.[Web of Science][Medline]
8. Pretlow,T.P., O'Riordan,M.A., Spancake,K.M. and Pretlow,T.G. (1993) Two types of putative preneoplastic lesions identified by hexosaminidase activity in whole-mounts of colons from F344 rats treated with carcinogen. Am. J. Pathol., 142, 1695–1700.[Abstract]
9. Shpitz,B., Hay,K., Medline,A., Bruce,W.R., Vivona,A., Gallinger,S., Bull,S. and Stern,H. (1993) Aberrant crypt foci: early markers of malignancy in rat colon carcinogenesis. Proc. Am. Assoc. Cancer Res., 34, A684.
10. Nucci,M.R., Robinson,C.R., Longo,P., Campbell,P. and Hamilton,S.R. (1997) Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Hum. Pathol., 28, 1396–1407.[Web of Science][Medline]
11. Roncucci,L., Modica,S., Pedroni,M., Tamassia,M.G., Ghidoni,M., Losi,L., Fante,R., Di Gregorio,C., Manenti,A., Gafa,L. and Ponz,d.L. (1998) Aberrant crypt foci in patients with colorectal cancer. Br. J. Cancer, 77, 2343–2348.[Web of Science][Medline]
12. Bjerknes,M., Cheng,H., Hay,K. and Gallinger,S. (1997) APC mutation and the crypt cycle in murine and human intestine. Am. J. Pathol., 150, 833–839.[Abstract]
13. Okonogi,H., Ushijima,T., Shimizu,H., Sugimura,T. and Nagao,M. (1997) Induction of aberrant crypt foci in C57BL/6N mice by 2-amino-9H-pyrido[2,3-b]indole (A alphaC) and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). Cancer Lett., 111, 105–109.[Web of Science][Medline]
14. Davies,M.J. and Rumsby,P.C. (1998) Long-term analysis of colonic aberrant crypt formation after treatment of Sprague-Dawley rats with azoxymethane. Teratog. Carcinog. Mutagen., 18, 183–197.[Web of Science][Medline]
15. Otori,K., Konishi,M., Sugiyama,K., Hasebe,T., Shimoda,T., Kikuchi-Yanoshita,R., Mukai,K., Fukushima,S., Miyaki,M. and Esumi,H. (1998) Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer, 83, 896–900.[Web of Science][Medline]
16. Wargovich,M.J., Harris,C., Chen,C.D., Palmer,C., Steele,V.E. and Kelloff,G.J. (1992) Growth kinetics and chemoprevention of aberrant crypts in the rat colon. J. Cell. Biochem., 16G (suppl.), 51–54.
17. Roncucci,L., Pedroni,M., Fante,R., Di Gregorio,C. and Ponz de Leon,M. (1993) Cell kinetic evaluation of human colonic aberrant crypts. Cancer Res., 53, 3726–3729.[Abstract/Free Full Text]
18. Yamashita,N., Minamoto,T., Onda,M. and Esumi,H. (1994) Increased cell proliferation of azoxymethane-induced aberrant crypt foci of rat colon. Jpn. J. Cancer Res., 85, 692–698.[Web of Science][Medline]
19. Takayama,T., Katsuki,S., Takahashi,Y., Ohi,M., Nojiri,S., Sakamaki,S., Kato,J., Kogawa,K., Miyake,H. and Niitsu,Y. (1998) Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med., 339, 1277–1284.[Abstract/Free Full Text]
20. Bouzourene,H., Chaubert,P., Seelentag,W., Bosman,F.T. and Saraga,E. (1999) Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum. Pathol., 30, 66–71.[Web of Science][Medline]
21. Siu,I.M., Robinson,D.R., Schwartz,S., Kung,H.J., Pretlow,T.G., Petersen,R.B. and Pretlow,T.P. (1999) The identification of monoclonality in human aberrant crypt foci. Cancer Res., 59, 63–66.[Abstract/Free Full Text]
22. Rihoux,J.P. and Nicolas,J.M. (1999) H1 antihistamines, cytochrome P450 and multidrug resistance: is there a link? Inflamm. Res., 48 (suppl. 1), S71–S72.
23. Kochevar,I.E., Moran,M., Lyon,N., Flotte,T., Siebert,E. and Gange,R.W. (1993) Effects of systemic indomethacin, meclizine and BW755C on chronic ultraviolet B-induced effects in hairless mouse skin. J. Invest. Dermatol., 100, 186–193.[Web of Science][Medline]
24. Gomez-Fabre,P.M., de Pedro,E., Medina,M.A., Nunez de Castro,I. and Marquez,J. (1997) Polyamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B. Cancer Lett., 113, 141–144.[Web of Science][Medline]
25. Medina,M.A., Garcia,d.,V., Morata,P., Lozano,J. and Sanchez-Jimenez,F. (1995) Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines.Breast Cancer Res. Treat., 35, 187–194 [Erratum (1996) Breast Cancer Res. Treat., 37, 97.[Web of Science][Medline]
26. Hiroi,T., Ohishi,N., Imaoka,S., Yabusaki,Y., Fukui,H. and Funae,Y. (1995) Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J. Pharmacol. Exp. Ther., 272, 939–944.[Abstract/Free Full Text]
27. Asanoma,M., Takahashi,K., Miyabe,M., Yamamoto,K., Yoshimi,N., Mori,H. and Kawazoe,Y. (1994) Inhibitory effect of topical application of polymerized ferulic acid, a synthetic lignin, on tumor promotion in mouse skin two-stage tumorigenesis. Carcinogenesis, 15, 2069–2071.[Abstract/Free Full Text]
28. Tanaka,T., Kojima,T., Kawamori,T., Wang,A., Suzui,M., Okamoto,K. and Mori,H. (1993) Inhibition of 4-nitroquinoline-1-oxide-induced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic acids. Carcinogenesis, 14, 1321–1325.[Abstract/Free Full Text]
29. Gann,P.H., Ma,J., Giovannucci,E., Willett,W., Sacks,F.M., Hennekens,C.H. and Stampfer,M.J. (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res., 59, 1225–1230.[Abstract/Free Full Text]
30. Giovannucci,E. (1999) Tomatoes, tomato-based products, lycopene and cancer: review of the epidemiologic literature. J. Natl Cancer Inst., 91, 317–331.[Abstract/Free Full Text]
31. Huang,Q., Lawson,T.A., Chung,F.L., Morris,C.R. and Mervish,S.S. (1993) Inhibition by phenylethyl and phenylhexyl isothiocyanate of metabolism of and DNA methylation by N-nitrosomethylamylamine in rats. Carcinogenesis, 14, 749–754.[Abstract/Free Full Text]
32. Hecht,S.S., Trushin,N., Rigotty,J., Carmella,S.G., Borukhova,A., Akerkar,S., Desai,D., Amin,S. and Rivenson,A. (1996) Inhibitory effects of 6-phenylhexyl isothiocyanate on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolic activation and lung tumorigenesis in rats. Carcinogenesis, 17, 2061–2067.[Abstract/Free Full Text]
33. Samaha,H.S., Kelloff,G.J., Steele,V., Rao,C.V. and Reddy,B.S. (1997) Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res., 57, 1301–1305.[Abstract/Free Full Text]
34. Yu,R., Mandlekar,S., Harvey,K.J., Ucker,D.S. and Kong,A.N. (1998) Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity. Cancer Res., 58, 402–408.[Abstract/Free Full Text]
35. Sumiyoshi,H. and Wargovich,M.J. (1990) Chemoprevention of 1,2-dimethylhydrazine-induced colon cancer in mice by naturally occurring organosulfur compounds. Cancer Res., 50, 5084–5087.[Abstract/Free Full Text]
36. Miller,M.R., McClure,D. and Shiman,R. (1976) Mechanism of inactivation of phenylalanine hydroxylase by p-chlorophenylalanine in hepatoma cells in culture. Two possible models. J. Biol. Chem., 251, 3677–3684.[Abstract/Free Full Text]
37. Carducci,M.A., Nelson,J.B., Chan-Tack,K.M., Ayyagari,S.R., Sweatt,W.H., Campbell,P.A., Nelson,W.G. and Simons,J.W. (1996) Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2, 379–387.[Abstract/Free Full Text]
38. Gore,S.D., Samid,D. and Weng,L.J. (1997) Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res., 3, 1755–1762.[Abstract]
39. Melchior,S.W., Brown,L.G., Figg,W.D., Quinn,J.E., Santucci,R.A., Brunner,J., Thuroff,J.W., Lange,P.H. and Vessella,R.L. (1999) Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int. J. Oncol., 14, 501–508.[Web of Science][Medline]
40. Marnett,L.J. (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52, 5575–5589.[Free Full Text]
41. Greenberg,E.R., Baron,J.A., Freeman,D.H.Jr, Mandel,J.S. and Haile,R. (1993) Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J. Natl Cancer Inst., 85, 912–916.[Abstract/Free Full Text]
42. Lippman,S.M., Toth,B.B., Batsakis,J.G., Weber,R.S., McCarthy,K.S., Hays,G.L., Wargovich,M.J., Lee,J.S., Thacher,S. and Lotan,R. (1990) Modulation by 13-cis retinoic acid of biologic markers as indicators of intermediate endpoints in human oral carcinogenesis. Prog. Clin. Biol. Res., 339, 179–191.[Medline]
43. Benner,S.E., Wargovich,M.J., Lippman,S.M., Fisher,R., Velasco,M., Winn,R.J. and Hong,W.K. (1994) Reduction in oral mucosa micronuclei frequency following alpha-tocopherol treatment of oral leukoplakia. Cancer Epidemiol. Biomarkers. Prev., 3, 73–76.[Abstract]
44. Kurie,J.M., Lee,J.S., Griffin,T., Lippman,S.M., Drum,P., Thomas,M.P., Weber,C., Bader,M., Massimini,G. and Hong,W.K. (1996) Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin. Cancer Res., 2, 287–293.[Abstract/Free Full Text]
45. Lippman,S.M. and Davies,P.J. (1997) Retinoids, neoplasia and differentiation therapy. Cancer Chemother. Biol. Response Modif., 17, 349–362.[Medline]
46. Papadimitrakopoulou,V.A., Hong,W.K., Lee,J.S., Martin,J.W., Lee,J.J., Batsakis,J.G. and Lippman,S.M. (1997) Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J. Natl Cancer Inst., 89, 257–258.[Free Full Text]
47. Lippman,S.M., Lotan,R. and Schleuniger,U. (1997) Retinoid-interferon therapy of solid tumors. Int. J. Cancer, 70, 481–483.[Web of Science][Medline]
48. Steele,V.E., Wargovich,M.J., Pereira,M.A., Rao,C.V., Lubet,R.A., Reddy,B.S. and Kelloff,G.J. (1999) Comparison of the azoxymethane (AOM)-induced rat colon crypt assay with the rat colon tumor assay for cancer chemopreventive agents. Proc. Am. Assoc. Cancer Res., 40, 57 (A377).

Received August 17, 1999; revised February 4, 2000; accepted February 17, 2000.

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				G. M. Lindzon, A. Medline, K.-J. Sohn, F. Depeint, R. Croxford, and Y.-I. Kim Effect of folic acid supplementation on the progression of colorectal aberrant crypt foci Carcinogenesis, September 1, 2009; 30(9): 1536 - 1543. [Abstract] [Full Text] [PDF]

				Y. NAKAYAMA, Y. INOUE, N. MINAGAWA, K. ONITSUKA, J. NAGATA, K. SHIBAO, K. HIRATA, T. SAKO, N. NAGATA, and K. YAMAGUCHI Chemopreventive Effect of 4-[3,5-Bis(trimethylsilyl) benzamido] Benzoic Acid (TAC-101) on MNU-induced Colon Carcinogenesis in a Rat Model Anticancer Res, June 1, 2009; 29(6): 2059 - 2065. [Abstract] [Full Text] [PDF]

				Z. Saidak, R. Mentaverri, and E. M. Brown The Role of the Calcium-Sensing Receptor in the Development and Progression of Cancer Endocr. Rev., April 1, 2009; 30(2): 178 - 195. [Abstract] [Full Text] [PDF]

				S. E. Bass, P. Sienkiewicz, C. J. MacDonald, R. Y.S. Cheng, A. Sparatore, P. Del Soldato, D. D. Roberts, T. W. Moody, D. A. Wink, and G. C. Yeh Novel Dithiolethione-Modified Nonsteroidal Anti-Inflammatory Drugs in Human Hepatoma HepG2 and Colon LS180 Cells Clin. Cancer Res., March 15, 2009; 15(6): 1964 - 1972. [Abstract] [Full Text] [PDF]

				Y.-I. Kim Folic Acid Supplementation and Cancer Risk: Point Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2220 - 2225. [Full Text] [PDF]

				G. Bobe, L. B. Sansbury, P. S. Albert, A. J. Cross, L. Kahle, J. Ashby, M. L. Slattery, B. Caan, E. Paskett, F. Iber, et al. Dietary Flavonoids and Colorectal Adenoma Recurrence in the Polyp Prevention Trial Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1344 - 1353. [Abstract] [Full Text] [PDF]

				L Ziliotto, L. Barbisan, and M. Rodrigues Lack of chemoprevention of dietary Agaricus blazei against rat colonic aberrant crypt foci Human and Experimental Toxicology, June 1, 2008; 27(6): 505 - 511. [Abstract] [PDF]

				R. A. Furtado, E. P. Rodrigues, F. R. R. Araujo, W. L. Oliveira, M. A. Furtado, M. B. Castro, W. R. Cunha, and D. C. Tavares Ursolic Acid and Oleanolic Acid Suppress Preneoplastic Lesions Induced by 1,2-Dimethylhydrazine in Rat Colon Toxicol Pathol, June 1, 2008; 36(4): 576 - 580. [Abstract] [Full Text] [PDF]

				N. L. Cho, M. Redston, A. G. Zauber, A. M. Carothers, J. Hornick, A. Wilton, S. Sontag, N. Nishioka, F. M. Giardiello, J. R. Saltzman, et al. Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial Cancer Prevention Research, June 1, 2008; 1(1): 21 - 31. [Abstract] [Full Text] [PDF]

				H. Xiao, X. Hao, B. Simi, J. Ju, H. Jiang, B. S. Reddy, and C. S. Yang Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats Carcinogenesis, January 1, 2008; 29(1): 113 - 119. [Abstract] [Full Text] [PDF]

				S. N. T. Ngo, D. B. Williams, L. Cobiac, and R. J. Head Does Garlic Reduce Risk of Colorectal Cancer? A Systematic Review J. Nutr., October 1, 2007; 137(10): 2264 - 2269. [Abstract] [Full Text] [PDF]

				L. M. Aleksunes and J. E. Manautou Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease Toxicol Pathol, June 1, 2007; 35(4): 459 - 473. [Abstract] [Full Text] [PDF]

				E. J. Quann, F. Khwaja, K. H. Zavitz, and D. Djakiew The Aryl Propionic Acid R-Flurbiprofen Selectively Induces p75NTR-Dependent Decreased Survival of Prostate Tumor Cells Cancer Res., April 1, 2007; 67(7): 3254 - 3262. [Abstract] [Full Text] [PDF]

				O. K. Glebov, L. M. Rodriguez, P. Soballe, J. DeNobile, J. Cliatt, K. Nakahara, and I. R. Kirsch Gene Expression Patterns Distinguish Colonoscopically Isolated Human Aberrant Crypt Foci from Normal Colonic Mucosa. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2253 - 2262. [Abstract] [Full Text] [PDF]

				M. J. Wargovich What Do Diet-Induced Alterations in Colorectal Polyps and Aberrant Crypts Indicate for Risk? J. Nutr., October 1, 2006; 136(10): 2679S - 2680S. [Full Text] [PDF]

				T. P. Ong, R. Heidor, A. de Conti, M. L. Z. Dagli, and F. S. Moreno Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase Carcinogenesis, June 1, 2006; 27(6): 1194 - 1203. [Abstract] [Full Text] [PDF]

				S. A. Ross, J. W. Finley, and J. A. Milner Allyl Sulfur Compounds from Garlic Modulate Aberrant Crypt Formation J. Nutr., March 1, 2006; 136(3): 852S - 854S. [Abstract] [Full Text] [PDF]

				K. M. Kim, J. J. Song, J. Y. An, Y. T. Kwon, and Y. J. Lee Pretreatment of Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene Expression J. Biol. Chem., December 9, 2005; 280(49): 41047 - 41056. [Abstract] [Full Text] [PDF]

				E. Y. Park, A. Dillard, E. A. Williams, E. T. Wilder, M. R. Pepper, and M. A. Lane Retinol Inhibits the Growth of All-Trans-Retinoic Acid-Sensitive and All-Trans-Retinoic Acid-Resistant Colon Cancer Cells through a Retinoic Acid Receptor-Independent Mechanism Cancer Res., November 1, 2005; 65(21): 9923 - 9933. [Abstract] [Full Text] [PDF]

				A. M. Vetrano, D. E. Heck, T. M. Mariano, V. Mishin, D. L. Laskin, and J. D. Laskin Characterization of the Oxidase Activity in Mammalian Catalase J. Biol. Chem., October 21, 2005; 280(42): 35372 - 35381. [Abstract] [Full Text] [PDF]

				L. D. Nadauld, D. N. Shelton, S. Chidester, H. J. Yost, and D. A. Jones The Zebrafish Retinol Dehydrogenase, rdh1l, Is Essential for Intestinal Development and Is Regulated by the Tumor Suppressor Adenomatous Polyposis Coli J. Biol. Chem., August 26, 2005; 280(34): 30490 - 30495. [Abstract] [Full Text] [PDF]

				R. de Moura Espindola, R. P. Mazzantini, T. P. Ong, A. de Conti, R. Heidor, and F. S. Moreno Geranylgeraniol and {beta}-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-{kappa}B activation Carcinogenesis, June 1, 2005; 26(6): 1091 - 1099. [Abstract] [Full Text] [PDF]

				R. E. Rudolph, J. A. Dominitz, J. W. Lampe, L. Levy, P. Qu, S. S. Li, P. D. Lampe, M. P. Bronner, and J. D. Potter Risk Factors for Colorectal Cancer in Relation to Number and Size of Aberrant Crypt Foci in Humans Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 605 - 608. [Abstract] [Full Text] [PDF]

				S. Chakrabarty, H. Wang, L. Canaff, G. N. Hendy, H. Appelman, and J. Varani Calcium Sensing Receptor in Human Colon Carcinoma: Interaction with Ca2+ and 1,25-Dihydroxyvitamin D3 Cancer Res., January 15, 2005; 65(2): 493 - 498. [Abstract] [Full Text] [PDF]

				J. E. Paulsen, E. M. Loberg, H. B. Olstorn, H. Knutsen, I.-L. Steffensen, and J. Alexander Flat Dysplastic Aberrant Crypt Foci Are Related to Tumorigenesis in the Colon of Azoxymethane-Treated Rat Cancer Res., January 1, 2005; 65(1): 121 - 129. [Abstract] [Full Text] [PDF]

				O. M. Sieber, K. M. Howarth, C. Thirlwell, A. Rowan, N. Mandir, R. A. Goodlad, A. Gilkar, B. Spencer-Dene, G. Stamp, V. Johnson, et al. Myh Deficiency Enhances Intestinal Tumorigenesis in Multiple Intestinal Neoplasia (ApcMin/+) Mice Cancer Res., December 15, 2004; 64(24): 8876 - 8881. [Abstract] [Full Text] [PDF]

				Z. Zhao, Y. Egashira, and H. Sanada Ferulic Acid Is Quickly Absorbed from Rat Stomach as the Free Form and Then Conjugated Mainly in Liver J. Nutr., November 1, 2004; 134(11): 3083 - 3088. [Abstract] [Full Text] [PDF]

				C. Jette, P. W. Peterson, I. T. Sandoval, E. J. Manos, E. Hadley, C. M. Ireland, and D. A. Jones The Tumor Suppressor Adenomatous Polyposis Coli and Caudal Related Homeodomain Protein Regulate Expression of Retinol Dehydrogenase L J. Biol. Chem., August 13, 2004; 279(33): 34397 - 34405. [Abstract] [Full Text] [PDF]

				A. P. Femia, P. Dolara, and G. Caderni Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis Carcinogenesis, February 1, 2004; 25(2): 277 - 281. [Abstract] [Full Text] [PDF]

				C. C. Ziegler, L. Rainwater, J. Whelan, and M. F. McEntee Dietary Resveratrol Does Not Affect Intestinal Tumorigenesis in ApcMin/+ Mice J. Nutr., January 1, 2004; 134(1): 5 - 10. [Abstract] [Full Text] [PDF]

				L. Mollersen, J. E. Paulsen, H. B. Olstorn, H. K. Knutsen, and J. Alexander Dietary retinoic acid supplementation stimulates intestinal tumour formation and growth in multiple intestinal neoplasia (Min)/+ mice Carcinogenesis, January 1, 2004; 25(1): 149 - 153. [Abstract] [Full Text] [PDF]

				L. Kopelovich, J. A. Crowell, and J. R. Fay The Epigenome as a Target for Cancer Chemoprevention J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757. [Abstract] [Full Text] [PDF]

				J. Carrier, A. Medline, K.-J. Sohn, M. Choi, R. Martin, S. W. Hwang, and Y.-I. Kim Effects of Dietary Folate on Ulcerative Colitis-Associated Colorectal Carcinogenesis in the Interleukin 2- and {beta}2-Microglobulin-deficient Mice Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1262 - 1267. [Abstract] [Full Text]

				E T Hawk and J L Viner Aspirin: still learning about the wonder drug Gut, November 1, 2003; 52(11): 1535 - 1536. [Full Text]

				B Shpitz, E Klein, G Buklan, D Neufeld, A Nissan, H R Freund, M Grankin, and J Bernheim Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer Gut, November 1, 2003; 52(11): 1598 - 1601. [Abstract] [Full Text] [PDF]

				Y.-I. Kim Role of Folate in Colon Cancer Development and Progression J. Nutr., November 1, 2003; 133(11): 3731S - 3739. [Abstract] [Full Text] [PDF]

				J. Kotsopoulos, K.-J. Sohn, R. Martin, M. Choi, R. Renlund, C. Mckerlie, S. W. Hwang, A. Medline, and Y.-I. J. Kim Dietary folate deficiency suppresses N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats Carcinogenesis, May 1, 2003; 24(5): 937 - 944. [Abstract] [Full Text] [PDF]

				S. Chakrabarty, V. Radjendirane, H. Appelman, and J. Varani Extracellular Calcium and Calcium Sensing Receptor Function in Human Colon Carcinomas: Promotion of E-Cadherin Expression and Suppression of {beta}-Catenin/TCF Activation Cancer Res., January 1, 2003; 63(1): 67 - 71. [Abstract] [Full Text] [PDF]

				K.-J. Sohn, J. M. Stempak, S. Reid, S. Shirwadkar, J. B. Mason, and Y.-I. Kim The effect of dietary folate on genomic and p53-specific DNA methylation in rat colon Carcinogenesis, January 1, 2003; 24(1): 81 - 90. [Abstract] [Full Text] [PDF]

				Y. Hirose, T. Kuno, Y. Yamada, K. Sakata, M. Katayama, K. Yoshida, Z. Qiao, K. Hata, N. Yoshimi, and H. Mori Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis Carcinogenesis, January 1, 2003; 24(1): 107 - 111. [Abstract] [Full Text] [PDF]

				V. E. Steele, C. W. Boone, D. Dauzonne, C. V. Rao, and R. V. Bensasson Correlation between Electron-donating Ability of a Series of 3-Nitroflavones and Their Efficacy to Inhibit the Onset and Progression of Aberrant Crypt Foci in the Rat Colon Cancer Res., November 15, 2002; 62(22): 6506 - 6509. [Abstract] [Full Text] [PDF]

				L. A. Cohen A Review of Animal Model Studies of Tomato Carotenoids, Lycopene, and Cancer Chemoprevention Experimental Biology and Medicine, November 1, 2002; 227(10): 864 - 868. [Abstract] [Full Text] [PDF]

				Y.-I. Kim, M. Hayek, J. B. Mason, and S. N. Meydani Severe Folate Deficiency Impairs Natural Killer Cell-Mediated Cytotoxicity in Rats J. Nutr., June 1, 2002; 132(6): 1361 - 1367. [Abstract] [Full Text] [PDF]

				G. Caderni, M.-G. Perrelli, F. Cecchini, and L. Tessitore Enhanced growth of colorectal aberrant crypt foci in fasted/refed rats involves changes in TGF{beta}1 and p21CIP expressions Carcinogenesis, February 1, 2002; 23(2): 323 - 327. [Abstract] [Full Text] [PDF]

				M. J. Wargovich, C. Woods, D. M. Hollis, and M. E. Zander Herbals, Cancer Prevention and Health J. Nutr., November 1, 2001; 131(11): 3034S - 3036. [Abstract] [Full Text] [PDF]

				A. Zalatnai, K. Lapis, B. Szende, E. Raso, A. Telekes, A. Resetar, and M. Hidvegi Wheat germ extract inhibits experimental colon carcinogenesis in F-344 rats Carcinogenesis, October 1, 2001; 22(10): 1649 - 1652. [Abstract] [Full Text] [PDF]

				A. Gupta, R. Nines, K. A. Rodrigo, R. A. Aziz, P. S. Carlton, D. L. Gray, V. E. Steele, M. A. Morse, and G. D. Stoner Effects of Dietary N-(4-Hydroxyphenyl)retinamide on N-Nitrosomethylbenzylamine Metabolism and Esophageal Tumorigenesis in the Fischer 344 Rat J Natl Cancer Inst, July 4, 2001; 93(13): 990 - 998. [Abstract] [Full Text] [PDF]

				J. Erik Paulsen, I.-L. Steffensen, E. M. Loberg, T. Husoy, E. Namork, and J. Alexander Qualitative and Quantitative Relationship between Dysplastic Aberrant Crypt Foci and Tumorigenesis in the Min/+ Mouse Colon Cancer Res., July 1, 2001; 61(13): 5010 - 5015. [Abstract] [Full Text] [PDF]

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (143) Request Permissions Google Scholar Articles by Wargovich, M. J. Articles by Kelloff, G. J. Search for Related Content PubMed PubMed Citation Articles by Wargovich, M. J. Articles by Kelloff, G. J. Social Bookmarking          What's this?

Online ISSN 1460-2180 - Print ISSN 0143-3334

Copyright © 2009 Oxford University Press

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals China Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics